The US Food and Drug Administration has stated it cannot determine whether PFAS ingredients in cosmetics are safe, because the available data are insufficient to support a conclusion either way.

The admission puts the regulator at the center of one of the most consequential open questions in beauty compliance: per- and polyfluoroalkyl substances, used or detected in products ranging from long-wear foundations to lipsticks and skin care, still lack a definitive federal safety verdict.

What did the FDA actually say?

The agency's position, as reported by Personal Care Insights, is straightforward: the science on PFAS in cosmetics is not complete enough for the FDA to make a safety determination. That is not a clearance, and it is not a ban. It is an explicit acknowledgment that the evidence base — covering exposure levels, absorption pathways and long-term effects from cosmetic use — does not yet support a regulatory conclusion.

For formulators, the practical takeaway is that PFAS remain in regulatory limbo at the federal level. The agency has not told brands to pull fluorinated ingredients, but it has also declined to affirm their safety.

Why the data gap matters commercially

PFAS have attracted scrutiny because of their persistence — they are widely described as "forever chemicals" — and their detection in cosmetics, whether as intentional functional ingredients or as trace contamination from manufacturing and packaging.

The absence of an FDA determination leaves brands carrying several distinct burdens:

• Reformulation risk. Any brand still specifying fluorinated compounds — for water resistance, slip or film-forming performance — cannot point to a federal green light, and may face consumer and retailer pressure before regulation forces a change.
• Supplier diligence. Trace PFAS can enter finished goods through raw materials and packaging. Buyers will need certificates and analytical data from suppliers, not just INCI declarations.
• State-level patchwork. While the federal position stays unresolved, US states have moved ahead with their own PFAS restrictions in cosmetics, meaning compliance teams must track a fragmented set of rules rather than one national standard.
• Testing demand. Brands preparing for state deadlines or voluntary claims like "PFAS-free" will need validated analytical methods to detect parts-per-billion-level fluorinated compounds.

What should compliance and R&D teams do now?

The FDA's data-gap statement effectively shifts the burden of proof onto industry. Companies that can fund or contribute exposure studies — through trade associations or direct research consortia — may help shape whatever determination eventually comes.

In the meantime, procurement teams can audit their portfolios for intentional PFAS use and query suppliers on unintended presence. Formulators can identify non-fluorinated alternatives that deliver comparable wear and water-resistance performance.

The next data point to watch: whether the FDA or industry groups move to fill the evidence gap with targeted toxicological and exposure studies, and whether additional US states impose their own cosmetic PFAS deadlines ahead of any federal conclusion.